|
|
|
Clinical Research Detail |
|
|
|
Title Of Study |
Phase 1 safety, tolerability, and pharmacokinetic study of Docetaxel nano-dispersion: A randomized, open label, dose ranging, active controlled, comparative, parallel groups, and multi-centric study.
|
|
|
Disease Condition |
Male or Female subjects with age 18 to 75-years inclusive, with histologically or cytologically confirmed diagnosis of cancer in advanced stage, potentially sensitive to single agent docetaxel; e.g. locally advanced or metastatic breast cancer, locally advanced non-small cell lung cancer, hormone refractory metastatic prostate cancer, other tumor type with no standard treatment, and performance status = 2 on the ECOG (Eastern Cooperative Oncology Group) performance scale.
|
|
|
Phase of Trial |
Phase-1
|
Discipline |
Oncology
|
|
|
Start date of Trial |
8/1/2010
|
Closing Date of Trial |
2/1/2011
|
|
|
|